微RNA-155作为生物标记物的作用在扩散型大B细胞淋巴瘤中
Epameinondas Koumpis1, Vasileios Georgoulis1, Konstantina Papathanasiou1
1Department of Hematology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.
Biomedicines
|January 8, 2025
概括
微RNA-155 (miR-155) 在扩散性大B细胞淋巴瘤 (DLBCL) 的发展和进展中起着关键作用. 了解miR-155的功能可能会导致这种侵袭性非霍奇金淋巴瘤的新诊断和预后生物标志物.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是最常见的侵袭性非霍奇金淋巴瘤 (NHL).
- 很大一部分DLBCL患者 (超过三分之一) 经历了疾病复发或折射性,尽管有新疗法.
- 微RNAs (miRNAs) 是基因表达的关键转录后调节者,与各种疾病有关.
研究的目的:
- 审查microRNA-155 (miR-155) 在DLBCL病变发生中的多方面的作用.
- 探索miR-155作为DLBCL诊断,预后和治疗预测的生物标志物的潜力.
主要方法:
- 文献综述侧重于DLBCL中miR-155的分子机制.
- 分析miR-155与其目标基因 (例如HDAC4,SOCS1) 的相互作用及其对细胞通路的影响.
- 检查miR-155对DLBCL瘤微环境和免疫反应的影响.
主要成果:
- miR-155是血液形成,炎症和与DLBCL相关的免疫反应的关键调节器.
- 包括HDAC4和SOCS1在内的miR-155目标是DLBCL病原体的组成部分.
- miR-155调节关键信号通路,转录因子和细胞因子表达,塑造DLBCL瘤微环境.
结论:
- miR-155深入参与扩散型大B细胞淋巴瘤的病理生理学.
- miR-155作为DLBCL患者的潜在诊断,预后和预测生物标志物具有显著的前景.
- 向miR-155或其通路可能为DLBCL提供新的治疗策略.
相关概念视频
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K


